|
|
Previous Article | Table of Contents | Next Article 
Blood, 1 May 2002, Vol. 99, No. 9, pp. 3419-3426
NEOPLASIA
Ectopic overexpression of second mitochondria-derived activator
of caspases (Smac/DIABLO) or cotreatment with N-terminus of
Smac/DIABLO peptide potentiates epothilone B derivative-(BMS
247550) and Apo-2L/TRAIL-induced apoptosis
Fei Guo,
Ramadevi Nimmanapalli,
Shanthi Paranawithana,
Sylvie Wittman,
David Griffin,
Purva Bali,
Erica O'Bryan,
Carlos Fumero,
Hong Gang Wang, and
Kapil Bhalla
From the Interdisciplinary Oncology Program, Moffitt
Cancer Center and Research Institute, University of South Florida,
Tampa, FL.
Second mitochondria-derived activator of caspases (Smac)/DIABLO is
a mitochondrial protein that is released into the cytosol along with
cytochrome c (cyt c) during the execution of the intrinsic pathway of
apoptosis. Smac/DIABLO promotes apoptosis by neutralizing the
inhibitory effect of the inhibitor of apoptosis (IAP) family of
proteins on the processing and activities of the effector caspases. Present studies demonstrate that, upon engagement of the mitochondrial pathway of apoptosis, epothilone (Epo) B derivative BMS 247550, a novel
nontaxane antimicrotubule agent, as well as the death ligand
Apo-2L/TRAIL (tumor necrosis factor- -related apoptosis-inducing ligand) induce the mitochondrial release and cytosolic accumulation of
Smac/DIABLO, along with cyt c, in human acute leukemia Jurkat T cells.
While it had no activity alone, ectopic overexpression of Smac/DIABLO
or treatment with the N-terminus heptapeptide (Smac-7) or tetrapeptide
(Smac-4) of Smac/DIABLO significantly increased Epo B- or
Apo-2L/TRAIL-induced processing and PARP cleavage activity of
caspase-3. This produced a significant increase in apoptosis of Jurkat
cells (P < .05). Increased apoptosis was also associated with the down-regulation of XIAP, cIAP1, and survivin. Along with the
increased activity of caspase-3, ectopic overexpression of Smac/DIABLO
or cotreatment with Smac-4 also increased Epo B- or Apo-2L/TRAIL-induced processing of caspase-8 and Bid, resulting in
enhanced cytosolic accumulation of cyt c. This was not due to increased
assembly and activity of Apo-2L/TRAIL-induced DISC (death-inducing
signaling complex) but dependent on the feedback activity of caspase-3.
These findings demonstrate that cotreatment with the N-terminus
Smac/DIABLO peptide is an effective strategy to enhance apoptosis
triggered by the death receptor or mitochondrial pathway and may
improve the antitumor activity of Apo-2L/TRAIL and Epo B.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
E. A. Perez
Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance
Mol. Cancer Ther.,
August 1, 2009;
8(8):
2086 - 2095.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Vucic and W. J. Fairbrother
The Inhibitor of Apoptosis Proteins as Therapeutic Targets in Cancer
Clin. Cancer Res.,
October 15, 2007;
13(20):
5995 - 6000.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. W. Meng, S.-H. Lee, H. Dai, D. Loegering, C. Yu, K. Flatten, P. Schneider, N. T. Dai, S. K. Kumar, B. D. Smith, et al.
MCL-1 as a Buffer for Proapoptotic BCL-2 Family Members during TRAIL-induced Apoptosis: A MECHANISTIC BASIS FOR SORAFENIB (BAY 43-9006)-INDUCED TRAIL SENSITIZATION
J. Biol. Chem.,
October 12, 2007;
282(41):
29831 - 29846.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Chauhan, P. Neri, M. Velankar, K. Podar, T. Hideshima, M. Fulciniti, P. Tassone, N. Raje, C. Mitsiades, N. Mitsiades, et al.
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)
Blood,
February 1, 2007;
109(3):
1220 - 1227.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S Mani, H. McDaid, A Grossman, F Muggia, S Goel, T Griffin, D Colevas, S. Horwitz, and M. Egorin
Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone
Ann. Onc.,
January 1, 2007;
18(1):
190 - 195.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Aleo, C. J. Henderson, A. Fontanini, B. Solazzo, and C. Brancolini
Identification of new compounds that trigger apoptosome-independent caspase activation and apoptosis.
Cancer Res.,
September 15, 2006;
66(18):
9235 - 9244.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. C. LaCasse, G. G. Cherton-Horvat, K. E. Hewitt, L. J. Jerome, S. J. Morris, E. R. Kandimalla, D. Yu, H. Wang, W. Wang, R. Zhang, et al.
Preclinical Characterization of AEG35156/GEM 640, a Second-Generation Antisense Oligonucleotide Targeting X-Linked Inhibitor of Apoptosis
Clin. Cancer Res.,
September 1, 2006;
12(17):
5231 - 5241.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. T. Schafer, A. B. Parrish, K. M. Wright, S. S. Margolis, J. R. Marks, M. Deshmukh, and S. Kornbluth
Enhanced Sensitivity to Cytochrome c-Induced Apoptosis Mediated by PHAPI in Breast Cancer Cells
Cancer Res.,
February 15, 2006;
66(4):
2210 - 2218.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Giagkousiklidis, M. Vogler, M.-A. Westhoff, H. Kasperczyk, K.-M. Debatin, and S. Fulda
Sensitization for {gamma}-Irradiation-Induced Apoptosis by Second Mitochondria-Derived Activator of Caspase
Cancer Res.,
November 15, 2005;
65(22):
10502 - 10513.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Z. Imam, J. Jankovic, S. F. Ali, J. T. Skinner, W. Xie, O. M. Conneely, and W.-D. Le
Nitric oxide mediates increased susceptibility to dopaminergic damage in Nurr1 heterozygous mice
FASEB J,
September 1, 2005;
19(11):
1441 - 1450.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Reed and M. Pellecchia
Apoptosis-based therapies for hematologic malignancies
Blood,
July 15, 2005;
106(2):
408 - 418.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Fischer and K. Schulze-Osthoff
New Approaches and Therapeutics Targeting Apoptosis in Disease
Pharmacol. Rev.,
June 1, 2005;
57(2):
187 - 215.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Rashmi, S. Kumar, and D. Karunagaran
Human colon cancer cells lacking Bax resist curcumin-induced apoptosis and Bax requirement is dispensable with ectopic expression of Smac or downregulation of Bcl-XL
Carcinogenesis,
April 1, 2005;
26(4):
713 - 723.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Guo, C. Sigua, P. Bali, P. George, W. Fiskus, A. Scuto, S. Annavarapu, A. Mouttaki, G. Sondarva, S. Wei, et al.
Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells
Blood,
February 1, 2005;
105(3):
1246 - 1255.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-Y. Wu, Y.-C. Chang, T.-L. Hsu, S.-L. Hsieh, and M.-Z. Lai
Sensitization of Cells to TRAIL-induced Apoptosis by Decoy Receptor 3
J. Biol. Chem.,
October 15, 2004;
279(42):
44211 - 44218.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Cummins, M. Kohli, C. Rago, K. W. Kinzler, B. Vogelstein, and F. Bunz
X-Linked Inhibitor of Apoptosis Protein (XIAP) Is a Nonredundant Modulator of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)- Mediated Apoptosis in Human Cancer Cells
Cancer Res.,
May 1, 2004;
64(9):
3006 - 3008.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q.-H. Yang and C. Du
Smac/DIABLO Selectively Reduces the Levels of c-IAP1 and c-IAP2 but Not That of XIAP and Livin in HeLa Cells
J. Biol. Chem.,
April 23, 2004;
279(17):
16963 - 16970.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Guo, C. Sigua, J. Tao, P. Bali, P. George, Y. Li, S. Wittmann, L. Moscinski, P. Atadja, and K. Bhalla
Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells
Cancer Res.,
April 1, 2004;
64(7):
2580 - 2589.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Waxman and P. S. Schwartz
Harnessing Apoptosis for Improved Anticancer Gene Therapy
Cancer Res.,
December 15, 2003;
63(24):
8563 - 8572.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Chauhan, G. Li, T. Hideshima, K. Podar, C. Mitsiades, N. Mitsiades, L. Catley, Y. T. Tai, T. Hayashi, R. Shringarpure, et al.
Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance
Blood,
November 1, 2003;
102(9):
3379 - 3386.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Krajewska, S. Krajewski, S. Banares, X. Huang, B. Turner, L. Bubendorf, O.-P. Kallioniemi, A. Shabaik, A. Vitiello, D. Peehl, et al.
Elevated Expression of Inhibitor of Apoptosis Proteins in Prostate Cancer
Clin. Cancer Res.,
October 15, 2003;
9(13):
4914 - 4925.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Greil, G. Anether, K. Johrer, and I. Tinhofer
Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools
J. Leukoc. Biol.,
September 1, 2003;
74(3):
311 - 330.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Nimmanapalli, E. O'Bryan, D. Kuhn, H. Yamaguchi, H.-G. Wang, and K. N. Bhalla
Regulation of 17-AAG--induced apoptosis: role of Bcl-2, Bcl-xL, and Bax downstream of 17-AAG--mediated down-regulation of Akt, Raf-1, and Src kinases
Blood,
July 1, 2003;
102(1):
269 - 275.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Yamaguchi, K. Bhalla, and H.-G. Wang
Bax Plays a Pivotal Role in Thapsigargin-induced Apoptosis of Human Colon Cancer HCT116 Cells by Controlling Smac/Diablo and Omi/HtrA2 Release from Mitochondria
Cancer Res.,
April 1, 2003;
63(7):
1483 - 1489.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Hunter, D. Kottachchi, J. Lewis, C. S. Duckett, R. G. Korneluk, and P. Liston
A Novel Ubiquitin Fusion System Bypasses the Mitochondria and Generates Biologically Active Smac/DIABLO
J. Biol. Chem.,
February 21, 2003;
278(9):
7494 - 7499.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Wittmann, P. Bali, S. Donapaty, R. Nimmanapalli, F. Guo, H. Yamaguchi, M. Huang, R. Jove, H. G. Wang, and K. Bhalla
Flavopiridol Down-Regulates Antiapoptotic Proteins and Sensitizes Human Breast Cancer Cells to Epothilone B-induced Apoptosis
Cancer Res.,
January 1, 2003;
63(1):
93 - 99.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. R. Arnt, M. V. Chiorean, M. P. Heldebrant, G. J. Gores, and S. H. Kaufmann
Synthetic Smac/DIABLO Peptides Enhance the Effects of Chemotherapeutic Agents by Binding XIAP and cIAP1 in Situ
J. Biol. Chem.,
November 8, 2002;
277(46):
44236 - 44243.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|